Traditional Chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses

Chang, 2020, Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China, JAMA, 323, 1092, 10.1001/jama.2020.1623 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. (2022) [2022-06-22]. https://covid19.who.int/. Leung, 2007, The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis, Am J Chin Med, 35, 575, 10.1142/S0192415X07005077 Li, 2012, Randomized controlled multicenter clinical trial for integrated treatment of community-acquired pneumonia based on traditional Chinese medicine syndrome differentiation, J Tradit Chin Med, 32, 554, 10.1016/S0254-6272(13)60070-9 Li, 2016, Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): a meta-analysis, J Chin Med Assoc, 79, 281, 10.1016/j.jcma.2015.10.009 Xiong, 2020, Traditional Chinese medicine in treating influenza: from basic science to clinical applications, Front Pharmacol, 11, 10.3389/fphar.2020.575803 Liu, 2021, Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis, Integr Med Res, 10, 10.1016/j.imr.2020.100644 Wang, 2021, Efficacy and safety of Qingfei Paidu decoction for treating COVID-19: a systematic review and meta-analysis, Front Pharmacol, 12 Wang, 2022, Chinese herbal medicine (“3 medicines and 3 formulations”) for COVID-19: rapid systematic review and meta-analysis, J Eval Clin Pract, 28, 13, 10.1111/jep.13614 Wu, 2021, Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: a systematic review and network meta-analysis, Medicine (Baltimore), 100, e27372, 10.1097/MD.0000000000027372 Wang, 2020, Exploring an integrative therapy for treating COVID-19: a randomized controlled trial, Chin J Integr Med, 26, 648, 10.1007/s11655-020-3426-7 Xiao, 2020, Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial, Pharmacol Res, 161, 10.1016/j.phrs.2020.105126 Hu, 2021, Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial, Phytomedicine, 85, 10.1016/j.phymed.2020.153242 Wu, 2022, Efficacy and safety of Chinese medicine for COVID-19: a systematic review and meta-analysis, Am J Chin Med, 50, 333, 10.1142/S0192415X22500136 Zhuang, 2021, A meta-analysis for Lianhua Qingwen on the treatment of Coronavirus disease 2019 (COVID-19), Complement Ther Med, 60, 10.1016/j.ctim.2021.102754 Luo, 2021, The add-on effect of Chinese herbal medicine on COVID-19: a systematic review and meta-analysis, Phytomedicine, 85, 10.1016/j.phymed.2020.153282 Shi, 2021, The effect of Chinese herbal medicine on digestive system and liver functions should not be neglected in COVID-19: an updated systematic review and meta-analysis, IUBMB Life, 73, 739, 10.1002/iub.2467 OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2. Oxford Centre for Evidence-Based Medicine. (2011) [2022-05-10]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence. Shea, 2017, AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both, BMJ, 358 Atkins, 2004, Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group, BMC Health Serv Res, 4, 38, 10.1186/1472-6963-4-38 Ang, 2020, Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of randomized controlled trials, J Clin Med, 9, 1583, 10.3390/jcm9051583 Du, 2021, Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: a systematic review and meta-analysis, PLoS One, 16, e0256429, 10.1371/journal.pone.0256429 Du, 2021, Add-on effect of honeysuckle in the treatment of coronavirus disease 2019: a systematic review and meta-analysis, Front Pharmacol, 12, 10.3389/fphar.2021.708636 Fan, 2020, Chinese herbal medicine for COVID-19: current evidence with systematic review and meta-analysis, J Integr Med, 18, 385, 10.1016/j.joim.2020.07.008 Fan, 2021, Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: a meta-analysis of randomized controlled trials, Medicine (Baltimore), 100, e26059, 10.1097/MD.0000000000026059 Zhou, 2021, Efficacy and safety of Chinese herbal decoction combined with Western medicine in treatment of COVID-19: a meta-analysis, Shi Yong Yi Xue Za Zhi, 37, 564 Li, 2021, Use of traditional Chinese medicine as an adjunctive treatment for COVID-19: a systematic review and meta-analysis, Medicine (Baltimore), 100, e26641, 10.1097/MD.0000000000026641 Liang, 2021, Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: a rapid systematic review and meta-analysis of randomized controlled trials, Complement Ther Med, 60, 10.1016/j.ctim.2021.102744 Liu, 2021, A review and meta-analysis of clinical efficacy and safety of integrated medicine on COVID-19, Zhong Yi Lin Chuang Yan Jiu, 13, 24 Pang, 2020, Chinese medical drugs for coronavirus disease 2019: a systematic review and meta-analysis, Integr Med Res, 9, 10.1016/j.imr.2020.100477 Sun, 2020, The role of Chinese medicine in COVID-19 pneumonia: a systematic review and meta-analysis, Am J Emerg Med, 38, 2153, 10.1016/j.ajem.2020.06.069 Wang, 2021, Efficacy and safety of traditional Chinese medicine in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Front Pharmacol, 12 Zhang, 2020, Meta-analysis of the efficacy and safety of Lianhua Qingwen combined with Western medicine in the treatment of common patients with new coronary pneumonia, Hainan Yi Xue Yuan Xue Bao, 26, 1045 Xiong, 2020, Chinese herbal medicine for coronavirus disease 2019: a systematic review and meta-analysis, Pharmacol Res, 160, 10.1016/j.phrs.2020.105056 Tang, 2021, Effect of Lianhua Qingwen preparation on COVID-19: a meta-analysis, Tianjin Zhong Yi Yao, 38, 1414 Yin, 2021, Efficacy of integrated traditional Chinese and Western medicine for treating COVID-19: a systematic review and meta-analysis of RCTs, Front Public Health, 9, 10.3389/fpubh.2021.622707 Zeng, 2020, Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019 (COVID-19): meta-analysis of randomized controlled trials, PLoS One, 15, e0238828, 10.1371/journal.pone.0238828 Kumar, 2022, Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis, J Biomol Struct Dyn, 40, 101, 10.1080/07391102.2020.1808072 Chatterjee, 2021, Click triazole as a linker for drug repurposing against SARs-CoV-2: a greener approach in race to find COVID-19 therapeutic, Curr Res Green Sustain Chem, 4, 10.1016/j.crgsc.2021.100064 Kumar, 2021, Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework, Sci Rep, 11, 7653, 10.1038/s41598-021-86986-6 Kumar, 2020, Design and optimization of a subunit vaccine targeting COVID-19 molecular shreds using an immunoinformatics framework, RSC Adv, 10, 35856, 10.1039/D0RA06849G Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). (2011) [2022-05-10]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence. PLoS Medicine Editors. Best practice in systematic reviews: the importance of protocols and registration. PLoS Med 2011;8(2):e1001009. Paez, 2017, Grey literature: an important resource in systematic reviews, J Evid Based Med, 10.1111/jebm.12266 Okagaki, 2016, The influence of funding sources on the scientific method, Mol Plant Pathol, 17, 651, 10.1111/mpp.12380 Schiavo, 2019, PROSPERO: an international register of systematic review protocols, Med Ref Serv Q, 38, 171, 10.1080/02763869.2019.1588072